Q1 FY27 results analysis · August 05, 2026

Aurobindo Pharma Ltd (AUROPHARMA) Q1 FY27 Results Analysis: PAT Jumps 25.2%, Gross Margin Expands 160 bps

+25.2%PAT year on year, Rs. 1,032.56 Cr
Cofacto ResearchPublished August 05, 20262 min readPositive read
Quick summary

Aurobindo Pharma Ltd's Q1 FY27 numbers came in strong, with revenue of Rs. 9,150.35 Cr (+16.30% YoY) and PAT growth of +25.20% YoY. Here's a quick read of what worked, what to watch, and what management said.

Quick Details
Results dateAugust 05, 2026
QuarterQ1 FY 2026-2027
Revenue (Q1)Rs. 9,150.35 Cr (+16.30% YoY)
PAT (Q1)Rs. 1,032.56 Cr (+25.20% YoY)
EBITDA margin20.56% (+18 bps YoY)
EPS (Q1)Rs. 17.86 (+25.80% YoY)
Market capRs. 93,830.78 Cr
CMPRs. 1,613.40

Quarter Snapshot

Auropharma delivered a solid Q1 with 16.3% YoY revenue growth and 25.2% PAT growth, driven by favourable forex tailwinds, Europe formulations momentum, and Pen-G turning EBITDA-positive. Gross margins expanded 160 bps YoY to 60.4%, while the recently closed Lannett acquisition and ongoing Pen-G/biosimilar ramp-up provide near-term catalysts toward the stated FY27 EBITDA margin target of >21%.

Key Investment Insights

Key Positives

  • Revenue grew 16.3% YoY to Rs.9,150.35 Cr, the fastest quarterly clip in several periods
  • PAT-to-owners grew 25.2% YoY to Rs.1,032.56 Cr, outpacing revenue growth
  • Gross margin expanded 160 bps YoY to 60.4%, the highest in the trailing year
  • EBITDA grew 17.3% YoY to Rs.1,880.96 Cr, with margin improving to 20.56% from 20.38% a year ago
  • Normalized PAT (excluding exceptional items) grew 28.5% YoY to Rs.1,059.40 Cr
  • Europe formulations momentum continues, having achieved €1 Bn annual revenue in FY26 (up 23.4% YoY)
  • Pen-G production is generating positive EBITDA, contributing to API growth

Risk Factors

  • Employee benefits expense grew 20.5% YoY (16.2% of revenue vs 15.6% a year ago), driven by annual increments and headcount additions
  • Effective Tax Rate jumped to 31.88% from 28.65% QoQ, reverting to year-ago level
  • Standalone revenue declined 1.71% YoY, reflecting the shift where subsidiary operations now drive group growth

Ask about this

Ask Cofacto a question about this result. Answers cite filings and company data.

Companies on this page

Related

Share on X · LinkedIn · WhatsApp

Disclaimer: This results analysis is published for educational and informational purposes only. It is not investment advice, not a recommendation to buy, sell or hold any security.